In humans with obesity and T2DM, a recent meta-analysis showed the combination of SGLT2 inhibitors and GLP-1RAs may be synergistic in improving insulin resistance, weight loss, and systolic blood pressure. The gene discussed is SLC5A2; the disease is Insulin resistance.